source
- Compass Pathways and Usona Institute vie for first FDA approval of a psilocybin depression therapyCompass Pathways and Usona Institute are both positioning themselves to become the first company with an FDA-approved psilocybin therapy for treatment-resistant depression. Compass has long been s…
- Scientists study blood markers for chronic traumatic encephalopathy using samples from 21 football playersResearchers collected blood from 21 current football players and arranged for their brains to be donated after death to support chronic traumatic encephalopathy (CTE) research. The team is analyzi…